SmartAnalyst

GSK / Valeant's epilepsy drug ezogabine gets positive vote from FDA panel in partial onset seizures http://on.wsj.com/bxVClv

Sounds like a legal tangle behind FDA's approval of generic Lovenox, the popular inpatient blood thinner http://on.wsj.com/bTlPqS

In wake of generic Lovenox, #Sanofi-Aventis circles #Genzyme for potential play in generic-proof biologic drugs http://on.wsj.com/9zejEg

Arena Pharma, Eisai to co-market promising obesity drug lorcaserin if approved. Japanese pharma on the prowl again! http://on.wsj.com/9blpyj

WSJ.com - Celgene to Buy Abraxis Bioscience for $2.9 Billion, Expanding Cancer Portfolio http://on.wsj.com/cfhltB

#Roche GLP-1 analog faces delays in this promising class of diabetes drugs http://www.bloomberg.com/apps/news?pid=20601202&sid=aKQ8.4T98.wU

#Novartis's MS pill Gilenia faces safety hurdles in advance of FDA panel: declining lung function and skin cancer http://bit.ly/d24jS0

Eli Lilly sets plans for emerging markets through marketing branded generics but not price-cutting (unlike others) http://on.wsj.com/9OUB4z

WSJ.com - AstraZeneca drug vandetanib may impede medullary thyroid cancer (previously failed for lung cancer) http://on.wsj.com/chNcvB

Winners from the cancer meeting #ASCO? Immunotherapies (ipilimumab and crizotinib), mBC drug erubilin and Avastin in ovarian cancer

#Vertex reports 75% patients with SVR for HCV drug telapravir; likely to be the runaway market leader in this space http://on.wsj.com/9sdYR9

2 drugs Rituxan & Revlimid can make cancers less fatal; does that mean cancer can be managed as a chronic disease? http://on.wsj.com/cG6Lub

#Astellas buys cancer biotech OSI for $4 billion. Only thing in doubt was how much more than $52 would Astellas pay http://on.wsj.com/df0ZCp

#Merck shuts down follow-on biologic in anemia but revives CETP inhibitors which Pfizer abandoned with torcetrapib http://on.wsj.com/aPrSz4

Does anyone even know the largest pharma company in Rx volume in the US? #Teva Pharmaceuticals http://nyti.ms/dl9VOb #pharma

#Genzyme is buckling the diversification trend by selling non-core businesses http://bit.ly/aVN5bR

Doesn't it seem like each new drug (approved or up-for-approval) is projected to earn $1 billion, which happens to be blockbuster status?

FDA rejects #Intermune drug for idiopathic pulmonary fibrosis ($1 billion?); can't get by with one weak positive trial http://nyti.ms/cWLwvw

Finally!! FDA approves Dendreon's cancer vaccine Provenge to tackle a death sentence--refractory prostate cancer http://on.wsj.com/ch5f0T

Novo Nordisk's Victoza is lifting sales guidance for the year, stealing share from Lilly's Byetta http://bit.ly/cxtdQA #FiercePharma